Skip to main content
. 2022 Feb 28;12(3):351. doi: 10.3390/life12030351

Figure 5.

Figure 5

Suppression of GCS enhances cisplatin sensitivity. (A) Inducible mRNA expression of GCS following low-dose cisplatin (0, 10, 20, and 40 μM). Cell viability of KKU-213A was determined after (B) GCS inhibition by siRNAs for 24 h and treated with cisplatin for 48 h, (C) GCS inhibition by PPMP for 24 h and in combination with cisplatin for 48 h, and (D) co-treatment of GCS with siRNAs and PPMP for 24 h plus cisplatin for 48 h. Values are expressed as the mean ± SEM of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 versus cisplatin at 0 µM.